---
layout: default
title: Norfloxacin
parent: 僅模型預測 (L5)
nav_order: 450
evidence_level: L5
indication_count: 10
---

# Norfloxacin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Norfloxacin: From Antibacterial Therapy to Polyclonal Hyperviscosity Syndrome

## One-Sentence Summary

> Norfloxacin is a fluoroquinolone antibacterial; regulatory records for Saudi Arabia contain no approved-indication text because the product is not currently marketed there.
> The TxGNN model's top-ranked prediction is **Polyclonal Hyperviscosity Syndrome**, but this signal is **not supported by any clinical trial or literature evidence**, and the drug's own evaluators flag it as a likely model artifact rather than a genuine repurposing hypothesis.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no approved-indication text exists because Norfloxacin is not marketed in Saudi Arabia |
| Predicted New Indication | Polyclonal Hyperviscosity Syndrome |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Saudi Arabia Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for Norfloxacin is not available in this evidence pack. Norfloxacin is generally known as a fluoroquinolone-class antibacterial, acting through inhibition of bacterial DNA gyrase/topoisomerase IV — a mechanism specific to bacterial nucleic acid replication.

Polyclonal hyperviscosity syndrome is a hematologic/plasma-protein disorder driven by excess immunoglobulin production, with no known pharmacological pathway overlapping with antibacterial DNA-gyrase inhibition. The model's own scoring rationale explicitly states that there is **no mechanistic link** between Norfloxacin and this disease, and it is judged to be **model noise** — a case where TxGNN assigns a high similarity score without any biologically plausible or evidence-backed basis.

Given the absence of any clinical trial or literature evidence, and the lack of a coherent mechanistic story, this specific top-ranked prediction should not be treated as an actionable repurposing hypothesis. It is retained in this report for transparency and audit purposes, consistent with the model's decision stage of S0 and recommendation of Hold.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Saudi Arabia Market Information

Norfloxacin currently holds no marketing authorization in Saudi Arabia (0 licenses on record), so no product/dosage-form/indication table can be generated.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked TxGNN prediction (Polyclonal Hyperviscosity Syndrome) has no supporting clinical trials or literature, no plausible mechanistic link, and is explicitly flagged as likely model noise. Evidence level is L5 (prediction only), which does not meet the bar for further clinical or regulatory action.

**To proceed, the following is needed:**
- TFDA/SFDA package insert data (warnings and contraindications) — currently a Blocking data gap preventing any safety pre-screening
- Confirmed mechanism-of-action (MOA) data from DrugBank to properly assess mechanistic plausibility for any candidate indication
- Saudi Arabia regulatory/marketing status confirmation, since Norfloxacin is currently unlicensed in-market
- Independent biological validation (in vitro/in vivo) if this indication is to be pursued further, given the current lack of any supporting evidence

**Note on other candidates in this evidence pack:** Among the 10 TxGNN-ranked predictions reviewed, **rank 10 (Septicemic Plague)** stands out with meaningfully stronger evidence (Evidence Level L3, decision stage S1, recommendation "Research Question") — fluoroquinolones as a class have documented activity against *Yersinia pestis*. However, the rationale also notes that Norfloxacin's own pharmacokinetic profile (low systemic bioavailability, weak tissue penetration) makes it a poor candidate compared to ciprofloxacin, levofloxacin, or doxycycline, which are the guideline-preferred agents. This class-level signal may warrant separate evaluation but does not change the Hold recommendation for the top-ranked prediction addressed in this report.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

